{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T01:08:59Z","timestamp":1766106539028,"version":"3.48.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,18]]},"DOI":"10.7759\/cureus.99571","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T01:04:38Z","timestamp":1766106278000},"source":"Crossref","is-referenced-by-count":0,"title":["Dasatinib-Associated Recurrent Symptomatic Bilateral Pleural Effusions in an Elderly Patient With End-Stage Renal Disease on Maintenance Hemodialysis"],"prefix":"10.7759","author":[{"given":"Macaulay A","family":"Onuigbo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Biediger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes JE","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, et al.. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016, 34:2333-40. 10.1200\/JCO.2015.64.8899","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.09.012","article-title":"Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management","volume":"17","author":"Cortes JE","year":"2017","unstructured":"Cortes JE, Jimenez CA, Mauro MJ, Geyer A, Pinilla-Ibarz J, Smith BD. Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management. Clin Lymphoma Myeloma Leuk. 2017, 17:78-82. 10.1016\/j.clml.2016.09.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17654","article-title":"Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients","volume":"194","author":"Rousselot P","year":"2021","unstructured":"Rousselot P, Mollica L, Guilhot J, et al.. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. Br J Haematol. 2021, 194:393-402. 10.1111\/bjh.17654","journal-title":"Br J Haematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17618","article-title":"What is the right dosage of dasatinib for treating chronic myeloid leukaemia?","volume":"194","author":"Hehlmann R","year":"2021","unstructured":"Hehlmann R. What is the right dosage of dasatinib for treating chronic myeloid leukaemia?. Br J Haematol. 2021, 194:234. 10.1111\/bjh.17618","journal-title":"Br J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian HM","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, et al.. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012, 119:1123-9. 10.1182\/blood-2011-08-376087","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah NP","year":"2016","unstructured":"Shah NP, Rousselot P, Schiffer C, et al.. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016, 91:869-74. 10.1002\/ajh.24423","journal-title":"Am J Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/437076-dasatinib-associated-recurrent-symptomatic-bilateral-pleural-effusions-in-an-elderly-patient-with-end-stage-renal-disease-on-maintenance-hemodialysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T01:04:38Z","timestamp":1766106278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/437076-dasatinib-associated-recurrent-symptomatic-bilateral-pleural-effusions-in-an-elderly-patient-with-end-stage-renal-disease-on-maintenance-hemodialysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.99571","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,18]]}}}